B4GALT5

B4GALT5 encodes a β-1,4-galactosyltransferase that synthesizes lactosylceramide (LacCer) from glucosylceramide, the committed precursor step for downstream glycosphingolipid biosynthesis (PMID:30114188, PMID:40036900). In the CNS, B4GALT5 acts redundantly with B4GALT6 to generate brain gangliosides: double knockout abolishes LacCer synthase activity and eliminates major gangliosides, and the resulting loss of ganglioside-laminin interaction impairs neurite outgrowth, perineuronal net formation, and axonal/myelin development (PMID:30114188). Its LacCer product is also the obligate precursor for the globoside Gb3, such that B4GALT5 disruption abolishes Gb3 and confers resistance to Shiga toxin binding and cytotoxicity (PMID:40036900). Beyond glycolipid synthesis, B4GALT5 participates in disease-associated signaling and protein glycosylation: it interacts with UGCG to drive a sphingolipid-ERK-oxidative stress axis promoting cardiomyocyte hypertrophy (PMID:37658291), binds laminin to activate Akt/GSK-3β/β-catenin signaling in cardiac fibrosis (PMID:38081351), suppresses MHC-I via the ERAD pathway to enable tumor immune evasion (PMID:40316305), and catalyzes N-glycosylation of YWHAZ (14-3-3ζ) at N95 to promote FOXO3a degradation during gastric carcinogenesis (PMID:42097241).

1. 2018 High

   Established that B4GALT5, acting redundantly with B4GALT6, is genetically required for LacCer synthase activity and ganglioside production in the CNS, resolving which enzyme(s) commit the ganglioside pathway in brain.

   Evidence CNS-specific B4galt5/B4galt6 double knockout mice with LacCer synthase activity assay and ganglioside profiling

   PMID:30114188

   Open questions at the time

   • Does not resolve the individual catalytic contribution of B4GALT5 versus B4GALT6 in non-CNS tissues
   • No structural basis for substrate specificity
2. 2018 High

   Connected ganglioside loss to a defined cellular mechanism by showing B4GALT5/6-dependent gangliosides mediate neurosphere-laminin interaction required for neurite outgrowth, PNN, and myelin formation.

   Evidence Neurosphere and neurite outgrowth/laminin adhesion assays from double KO mice plus in vivo immunohistochemistry

   PMID:30114188

   Open questions at the time

   • Which specific ganglioside species mediates laminin binding is not pinpointed
   • Molecular receptor linking gangliosides to laminin not identified
3. 2018 Low

   Tested whether B4GALT5 acts on viral glycoproteins, finding the porcine ortholog interacts with and co-localizes with PRRSV GP5 in the Golgi and modestly restricts viral replication.

   Evidence Co-IP and confocal co-localization in porcine cells with overexpression viral titer measurement

   PMID:29546034

   Open questions at the time

   • Single Co-IP in porcine ortholog without reciprocal validation
   • Restriction effect modest and mechanistically undefined
   • Human relevance not established
4. 2023 Medium

   Placed B4GALT5 downstream of UGCG in a sphingolipid-driven cardiac hypertrophy pathway, addressing how glucosylceramide synthesis feeds hypertrophic signaling.

   Evidence Co-IP plus B4GalT5 knockdown rescue of UGCG-driven hypertrophy with ERK/oxidative-stress readouts in vitro and pressure-overload model

   PMID:37658291

   Open questions at the time

   • Whether the effect requires B4GALT5 catalytic activity or only physical interaction unclear
   • Single lab
5. 2023 Medium

   Identified a laminin-binding, pro-fibrotic role for B4GALT5 via Akt/GSK-3β/β-catenin activation in fibroblast-to-myofibroblast transition.

   Evidence AAV9 knockdown in TAC model, in vitro overexpression, laminin Co-IP, and pathway/collagen analysis

   PMID:38081351

   Open questions at the time

   • Direct vs indirect nature of laminin interaction not fully resolved
   • Single lab
   • Catalytic dependence not tested
6. 2025 Medium

   Defined a non-glycolipid immune-evasion mechanism in which B4GALT5 suppresses MHC-I through ERAD, attenuating CD8+ T-cell surveillance of pancreatic cancer.

   Evidence RNA-seq, Co-IP, knockdown/overexpression in PDAC cells, and in vivo tumor-infiltrating CD8+ T-cell quantification

   PMID:40316305

   Open questions at the time

   • ERAD substrate directly engaged by B4GALT5 not identified
   • Whether MHC-I suppression depends on glycosyltransferase activity unclear
   • Single lab
7. 2025 High

   Confirmed B4GALT5 as the LacCer synthase generating the Gb3 receptor for Shiga toxin, distinguishing its glycolipid role from glycoprotein-based glycotopes.

   Evidence CRISPR/Cas9 knockout in CHO-Lec2 cells with Gb3/P1 glycolipid analysis and Shiga toxin binding/cytotoxicity assays

   PMID:40036900

   Open questions at the time

   • Does not address redundancy with B4GALT6 in this system
   • Tissue-specific contribution to Gb3 in humans not measured
8. 2025 Medium

   Identified miR-491-5p as a post-transcriptional repressor of B4GALT5 that limits airway smooth muscle proliferation and oxidative stress in asthma.

   Evidence Dual-luciferase 3'-UTR reporter, miR mimic transfection, and OVA-induced asthma mouse model with AAV-miR-491-5p

   PMID:40896538

   Open questions at the time

   • Which downstream B4GALT5 product mediates the asthma phenotype not defined
   • Single lab
9. 2025 Low

   Proposed B4GALT5 as a translationally upregulated node downstream of eIF2B that remodels membrane glycosphingolipids to promote mutant KRAS nanoclustering.

   Evidence Translational regulation and GSL profiling with KRAS nanoclustering/activity assays (preprint)

   Open questions at the time

   • Preprint, not peer reviewed
   • B4GALT5 is one step in a broader eIF2B/KRAS pathway and its specific necessity is not isolated
10. 2026 Medium

    Demonstrated B4GALT5 directly glycosylates a protein substrate, N-glycosylating YWHAZ at N95 to enhance FOXO3a binding and degradation during gastric carcinogenesis, extending its activity beyond glycolipids.

    Evidence Lectin microarray, Co-IP, YWHAZ N95 site-directed mutagenesis, and in vivo tumor-bearing mouse model

    PMID:42097241

    Open questions at the time

    • Whether protein N-glycosylation is a general B4GALT5 activity or YWHAZ-specific unknown
    • Single lab
    • Structural/enzymatic detail of protein glycosylation absent

• It remains unresolved whether B4GALT5's disease-associated signaling roles (cardiac, tumor immune, protein glycosylation) depend on its canonical LacCer synthase catalytic activity or on activity-independent protein interactions.
• No catalytic-dead mutant tested in cardiac, immune, or protein-glycosylation contexts
• No structural model of substrate engagement